Kornimate/medical-research-clean huggingface dataset:
patients' outcome with severe or fulminant hepatic insufficiency, hospitalized in the public hospitals of paris

Conditions: Fulminating Hepatic Failure

Summary: the main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with severe, fulminating acute liver failure in the public hospitals of paris.

severe, fulminating acute liver failure is a rare but serious disease. the overall prognosis has improved in recent years thanks to advances in medical management and liver transplantation. however, the epidemiology of this disease in france, the survival with or without liver transplantation of these patients and the factors that can influence this survival are not well known. the main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with severe, fulminating acute liver failure in the public hospitals of paris (aphp). the data will come from the aphp health data warehouse

Eligibility criteria:
inclusion criteria: * age \> 15 * severe liver failure or toxicants that may cause a liver failure or * (pr\ 1.5) and alt \>250 exclusion criteria: * patients with underlying chronic liver disease * patients with the conditions given by this following icd (international classification of diseases) : b18 - e831 - k70 - k715 - k717 - k730- k731 - k732 - 738 - k74 - k753 - k758 - k760 - k761
comparison of buprenorphine to morphine in treatment of neonatal abstinence syndrome (nas)

Conditions: Neonatal Abstinence Syndrome; Neonatal Withdrawal Syndrome

Summary: the purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost effective treatment alternative to morphine sulfate in the treatment of neonatal abstinence syndrome (nas).

neonatal abstinence syndrome is a condition that affects newborns who are exposed to chronic opioid drugs while they are in a mother's uterus (womb) prior to birth. the current standard of care treatment includes morphine sulfate. buprenorphine is a drug used in adults to treat narcotic dependence and withdrawal, but has not yet been approved for use in newborns as a treatment alternative for neonatal abstinence syndrome. this investigation is designed to measure if sublingual (under the tongue) buprenorphine is able to reduce hospital length of stay and decrease number of days of drug treatment currently required in treatment of nas. another goal will be to understand buprenorphine as a cost effective treatment for nas.

Eligibility criteria:
inclusion criteria: * infants of corrected gestational age ≥37 weeks * chronic opioid exposure in utero * signs and symptoms of nas requiring treatment * 2 consecutive finnegan scores ≥8 or any single score ≥12 exclusion criteria: * concomitant maternal benzodiazepine or alcohol use 30 days prior to enrollment * life-threatening congenital malformations * intrauterine growth retardation * seizure activity or congenital neurologic abnormalities * concomitant neonatal use of cytochrome p450 inhibitor or inducers prior to treatment * inability of mother's consent due to altered mental status or comorbid psychiatric disorder * neonatal administration of morphine prior to enrollment into study
studying biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial pog-9421

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial pog-9421.

objectives: * to profile basal and potentiated phospho-protein networks (pppns) using tissue samples from pediatric patients with de novo acute myeloid leukemia (aml) previously enrolled on clinical trial pog-9421. * to classify aml-based signal transduction mechanisms. * to correlate profiles of basal and pppns with specific molecular lesions (e.g., flt3-itd, npm, wt1, c-kit, cepbα, pasgδ75, and karyotype) and profiles of gene expression in tumor tissue samples. outline: banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia, meeting 1 of the following criteria: * primary induction failure (i.e., failed to achieve remission within the first 60 days of therapy) * relapsed disease (early or late) * in continuous complete remission * previously enrolled on pog-9421 * tissue samples available patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia
covid-19 serologies among healthcare workers at chsd (sero2)

Conditions: COVID-19; COVID-19 Serological Testing; COVID-19 Vaccines; Health Personnel; Antibodies, Viral; Seroepidemiologic Studies

Summary: this study looks at how many healthcare workers at chsd hospital developed antibodies against covid-19 after the second and third waves of the pandemic and after receiving a vaccine. it aims to better understand who might still be at risk of infection, how long immunity lasts after getting covid or the vaccine, and how reliable previous antibody tests were. blood samples will be collected from volunteer hospital staff during a one-month period to measure their antibody levels and compare them to earlier results.


Eligibility criteria:
inclusion criteria: - volunteers from the hospital staff who have signed a new informed consent form exclusion criteria: * refusal to participate (no signed consent form) * staff unavailable during the blood sampling period * participation only in the first seroprevalence survey without consent for the second
a time-motion study comparing self- to nurse-vaccination with influenza vaccine

Conditions: Influenza; Vaccination Site Reactions (HT)

Summary: the investigators hypothesize that people working in an acute care hospital setting will be able to successfully self-administer the intradermal vaccine (intanza) in less time than nurse-administration of the regular intramuscular influenza vaccine (vaxigrip). the investigators also hypothesize that people administering the intradermal vaccine for the second time will take less time to successfully administer than people administering it for the first time.

vaccination of healthcare workers has been shown to reduce mortality and morbidity in the patients they care for, as well as reducing illness and absenteeism in the healthcare workers themselves, and healthcare worker vaccination programs have been shown to be cost-effective for hospitals because of the reduced absenteeism. although influenza vaccination programs based on nurse-administered intramuscular vaccination are effective, easy access to vaccination for hospital staff remains a challenge, in part because of large numbers of staff working evening, night and weekend shifts. in addition, in the canadian setting, increasing the efficiency of all hospital programs is a priority. if regular recipients of seasonal vaccine became accustomed to the practice, self-administration may significantly improve the efficiency of pandemic mass vaccination campaigns.

Eligibility criteria:
inclusion criteria: * medically stable men or women 18 to 69 years of age (inclusive) * work in any capacity (including physicians and midwives with admitting privileges), volunteer, or student at participating hospital * able to read, understand, and respond to questionnaires * able to read, understand, and sign an informed consent form * available for follow-up for 8 days post-vaccination * participants in part b (repeat administration) of the study must also have participated in the previous randomized control trial of self- versus nurse-administered intradermal influenza vaccine and must have attempted to self-administer the vaccine exclusion criteria: * already received 2012-13 influenza vaccine * history of a severe reaction following influenza vaccination * known allergy to components of study vaccines (intanza® or vaxigrip®) * history of guillain-barré syndrome (gbs) within 8 weeks following influenza vaccination * acute febrile illness (\>37.9ºc orally) within the past 48 hours (participation may be deferred until recovery for these subjects)

Keywords: influenza vaccine administration
local control after robot-assisted supraglottic laryngectomy

Conditions: Supraglottic Squamous Cell Carcinoma

Summary: transoral robotic surgery is an option to treat supraglottic squamous cell carcinomas. oncological outcomes 2 years after transoral robotic surgery for supraglottic laryngectomy were studied.


Eligibility criteria:
inclusion criteria: * men or women over 18 years of age * patients with supra-glottic squamous cell carcinoma from t1 to t3, all stages n * patients with a robot assisted supra-glottic laryngectomy with at least 2 years follow-up exclusion criteria: * patients for whom follow-up of at least 2 years has not been achieved; * major patients protected by the law (under guardianship or guardianship); * patients who expressed opposition to their participation in the study.
pilot study of autna i

Conditions: Retinitis Pigmentosa

Summary: the objective of the study is to evaluate: 1. safety of autna i for subretinal implantation in patients with retinitis pigmentosa; 2. efficacy of autna i for subretinal implantation in patients with retinitis pigmentosa.

in this study, autna i (nanoparticle-decorated tio2 nanowire arrays), which is designed to replace the damaged photoreceptors in rp patients, was implanted in one eye of the subjects. the change or improvement in the visual acuity of the subjects, as well as the potential side effects, was then fully evaluated.

Eligibility criteria:
inclusion criteria: 1. age: 18-65 years of age. 2. clinically diagnosed as retinitis pigmentosa (one of the following two conditions): ① typical triadfundus manifestations: "osteoblastic" pigmentation of retina, arterial stenosis, and waxy atrophy of optic disc. ② typical fundus changes with both a and b, with or without c: 1. poor night vision before vision loss; 2. standard 5 erg examination showing more severely damaged scotopic response than photopic, even non response 3. impaired peripheral visual field in perimetry (when the patient's vision permits). 3. no or suspicious light perception in the eye for autna i implantation. 4. intact inner retinal structure on oct. no macular retinal or choroidal neovascularization. 5. voluntary to participate in the study and sign the informed consent. exclusion criteria: 1. entities that might interfere with the functioning of autna i, e.g. open ocular trauma, retinal detachment, glaucoma, severe uveitis, etc. 2. uncontrolled systemic diseases including hypertension (systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg), diabetes (blood glucose ≥8.0mmol/l with medication); 3. allergic constitution. 4. entities that might prevent the observation of the fundus, e.g. corneal opacity, etc. 5. ocular disease not suitable for undertaking the implantation surgery, e.g. corneal ulcers, etc. 6. habits of rubbing the eyes. 7. compromised liver function (alt and ast 1.5 times over the normal limits), renal function (cr 1.5 times over the normal limits), coagulation function (aptt 1.5 times over the normal limits). 8. pregnancy, lactating or planning to be pregnant within 6 months. 9. history of epilepsy or serious psychiatric diseases. 10. other local or systemic diseases that may affect the vision. 11. participation in other clinical trials within 1 month before this study. 12. other conditions that the researcher found imporper to be included into this study.
treating psychosocial distress in glaucoma

Conditions: Glaucoma, Primary Open Angle; Distress, Emotional; Anxiety; Depression

Summary: in this study, using three phases, the investigators will use an iterative development approach to refine a behavioral intervention for managing concomitant psychosocial distress in glaucoma. phase 1: the investigators will begin by developing a baseline intervention using strategies from acceptance and commitment therapy (act), and delivered using a mobile application. phase 2: the investigators will refine the baseline intervention for glaucoma patients using qualitative interviews conducted with primary open-angle glaucoma (poag) patients with psychosocial distress (n=20), and health professionals (n=5). phase 3: finally, the investigators will measure acceptability and feasibility of the refined intervention through a single-armed pilot study (n=25). the investigators hypothesize that the refined intervention will yield an acceptable and feasible intervention in a poag patient population, setting the stage for a future efficacy study.


Eligibility criteria:
inclusion criteria * diagnosed with mild, moderate, or severe chronic glaucoma (e.g., poag), * had a visual field within the past year at the main duke eye center, * been prescribed pressure lowering eye drop medication, * at least mild distress (based on phq-4), * 18 years old, * able to understand, speak, and read english, and * be able to provide informed consent. exclusion criteria * diagnosed with borderline glaucoma or as a glaucoma suspect, * had a glaucoma surgery in past month (e.g., trabeculectomy, glaucoma drainage device/tube), * visual acuity of worse than 20/70 in the better seeing eye, * diagnosed with a major medical conditions (e.g., cancer, or another visual disorder, like macular degeneration), * diagnosed with a psychiatric conditions (e.g., schizophrenia, bipolar disorder), and * reported or suspected cognitive impairment indicated by provider or chart review.
fecal biomarker study for patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the present study will analyze fecal levels of fc and fl in uc patients who relapse (flare) while on a qd or a bid asacol treatment regimen and compare those levels to levels of fc and fl in uc patients who do not relapse (flare).


Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent for this biomarker study; * be enrolled in study 2007021 (qdiem). exclusion criteria: * meet the qdiem protocol 2007021 for exclusion criteria
normal values for 3d high resolution anorectal manometry in children

Conditions: Children; Anorectal Disorder

Summary: anorectal 3d high resolution manometry (3d hrm) is the most advanced version of manometry equipment and has been recently introduced into clinical practice. it is the most precise method to assess the anal sphincter pressure function and may be crucial for planning and controlling surgical procedures of the anorectal area. normal values in pediatric population have not been established. the aim of this study is complex evaluation of anorectal function in children without symptoms from lower gi tract and establishment of normal values.


Eligibility criteria:
inclusion criteria: * parental agreement * age: 1 to 18 yr exclusion criteria: * parental disagreement * children younger than 1 yr * children after the surgery for anorectal malformations * children with constipation during the last 10 months * children with nonretentive fecal soiling * children with inflammatory bowel diseases or any other type of large bowel inflammation * children with anal fissure, anal varices, inflammation of the anorectal area or any other disease that may interfere with function of anorectum
effectiveness of silver diamine fluoride in arresting dental caries

Conditions: Dental Caries in Children

Summary: the present study aims to evaluate, through a controlled clinical randomized study,the effectiveness of silver diamine fluoride in arresting dentin caries lesions in primary molars when compared to atraumatic restorative treatment.

the present controlled clinical randomized study aiming at evaluating the effectiveness of silver diamine fluoride (sdf) in arresting dentin caries lesions on the occlusal surface of primary molars when compared to atraumatic restorative treatment (art). for this, 118 healthy children aged 2-5 years with at least one active dentin carious lesion, with no signs of pain or pulp involvement. the participants will be allocated randomly to one of two treatment groups: (1) test group - sdf and (2) control group - art. the international caries detection and assessment system (icdas) will be used to determine caries diagnosis and activity. in both groups, the guardians and children will receive oral hygiene instructions and will be advised about eating habits and fluoride dentifrice use.the clinical success will be verified through examinations performed by a blinded operator, after 3, 6 and 12 months, with clinical evaluations to detect caries arresting, representing the primary outcome of the study.

Eligibility criteria:
inclusion criteria: * children * aged 2 to 5 years; * who are in good general health; * have at least one active dentin carious lesion on the occlusal surface of primary molars corresponding to icdas codes 5 or 6. exclusion criteria: * children * with systemic or neurological diseases; * whose families intend to move from rio de janeiro next year; * with a history of allergy to silver or any substance present in the different materials to be used for treatment. teeth * with spontaneous or provoked pain, dental mobility or radiographic signs of involvement or possible pulp involvement; * shows possible pulp involvement by radiographic examination

Keywords: tooth, deciduous dental caries glass ionomer cements dental atraumatic restorative treatment cariostatic agents fluorides
mr-adaptive radiation therapy for anal cancer with escalated-treatment in a risk-optimized approach

Conditions: Anal Squamous Cell Carcinoma

Summary: the proposed study is a phase ii, single arm, open-label trial of mr-guided radiation therapy (rt) with risk stratified rt dose selection in patients with anal cancer. based on previous data, a risk adaptive treatment approached is proposed in 4 groups: low risk, standard risk, intermediate risk, and high risk. human papillomavirus (hpv) dna will be analyzed to identify novel biomarkers that predict chemoradiotherapy (crt) response and toxicity.

after being informed about the study and potential risks, all patients giving written informed consent will undergo a risk-stratified dose of treatment (radiation dose and chemotherapy number of cycles) based on predefined clinical and biological biomarkers for anal squamous cell carcinoma (scc). radiotherapy will be delivered on the mr-linac for image-guided-radiation therapy (igrt). patients will be followed for up to 5 years after radiotherapy and be required to complete questionnaires and clinic visits. patients have the option to complete blood and tissue samples during the study.

Eligibility criteria:
inclusion criteria: * patients with pathologically proven diagnosis of anal scc. this may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. individuals with squamous cell carcinoma of the anal margin are eligible. * clinical stage t1-4 n0-1 m0 (the union for international cancer control (uicc) / the american joint committee on cancer (ajcc) 8th ed) * patients must be eligible for definitive rt or crt * must be ≥ 18 years of age * must have an eastern cooperative oncology group (ecog) performance status of 0-2 exclusion criteria: * previous chemotherapy, rt or curative-intent surgical treatment (i.e. apr) for anal cancer. * any previous rt to the abdomino-pelvic region that would result in overlap of rt volume for the current study. * individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
naltrexone as adjunct in alcoholic cocaine dependent patients - 4

Conditions: Alcohol-Related Disorders; Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate naltrexone as an adjunct in alcoholic cocaine dependent patients; concurrent relapse prevention theory.


Eligibility criteria:
please contact site for information.

Keywords: alcohol dependence
the effects of acetylcysteine on alleviating damage of oxidative stress in hemodialysis patients

Conditions: Anemia; Atherosclerosis; End-Stage Renal Disease; Oxidative Stress; Pro-Inflammation

Summary: the aim of this study is to explore and identify the effects of acetylcysteine, a common mucolytic with anti-oxidant property, on alleviating the damage caused by increased oxidative stress in hemodialysis patients.

oxidative stress in patients with renal failure is higher than in healthy controls. once undergoing hemodialysis (hd) therapy, patients with end-stage renal disease even have more oxidative stress. reactive oxygen species (ros) denature the vital molecules, such as lipids, proteins, and nucleic acids. increased ros produce oxidized low-density lipoproteins (ox-ldl), which, in turn, induce atherosclerosis and subsequent cardiovascular disease. cardiovascular disease is the leading cause of death of hd patients. on the other hand, ros damage rbc membrane and cause hemolysis. hemolysis exaggerates uremic anemia and results in resistance to erythropoietin (epo) therapy. acetylcysteine, a common mucolytic, is an antioxidant as well. in vivo experiments, acetylcysteine has been demonstrated to inhibit the production of ox-ldl by ros. acetylcysteine has also been shown as an effective drug for prevention of contrast media-induced nephropathy in high-risk patients. thus we hypothesize hd patients taking acetylcysteine may have less ox-ldl produced by ros and, consequently, lower risk of cardiovascular disease. moreover, having less damage to rbc membrane by ros, hd patients taking acetylcysteine may have milder anemia and better responsiveness to erythropoietin therapy. therefore, we plan to conduct a prospective trial, in which acetylcysteine is administrated to the enrolled hd patients for three months. the primary goals of the study are to realize the changes of 1) plasma ox-ldl levels, 2) the anemia status, 3) the responsiveness to epo therapy, and 4) severity of atherosclerosis. the secondary goals are to identify the changes of oxidative stress and pro-inflammatory status in the patients.

Eligibility criteria:
inclusion criteria: * on hd thrice a week at our hd unit for more than three months * informed consent * the dose of epo and iron supplement is stationary in the previous one month * no taking acetylcysteine in previous one month * no using vitamin e-bonded dialysis membrane exclusion criteria: * severe liver disease (ast or alt \>40 iu/l), proven malignancy, and severe cardiovascular disease (proved by cardiac catheter or echography examination) * active infection or hospitalization in previous one month * clinically significant bleeding episode in previous one month * taking vitamin c, vitamin e or other known antioxidants.

Keywords: anemia atherosclerosis end-stage renal disease erythropoietin hemodialysis oxidative stress pro-inflammation